Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.
Novo Nordisk has made Wegovy HD, its 7.2 mg once-weekly semaglutide injection, available nationwide in the United States as of today, representing the highest-dose formulation of the therapy to date. The launch follows FDA approval in March under the agency's National Priority Review Voucher program, and is backed by the STEP UP trial, which demonstrated a mean weight loss of approximately 20.7 percent in adults with obesity, compared to roughly 17.5 percent at the 2.4 mg dose.
Gilead Sciences has agreed to acquire Tubulis GmbH, a Munich-based clinical-stage biotech developing next-generation antibody-drug conjugates, for $3.15 billion in upfront cash plus up to $1.85 billion in milestone payments, a total potential deal value of $5 billion. The acquisition adds two ADC assets in clinical development, including TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC currently in Phase Ib/II for platinum-resistant ovarian cancer and non-small cell lung cancer, and TUB-030, a 5T4-targeted ADC with early clinical signals across solid tumor types. Tubulis will operate as a dedicated ADC research organization within Gilead following close, which is expected in the second quarter of 2026, with the Munich site serving as a hub for the company's expanded ADC innovation effort.
Finally, today is World Health Day 2026, and Pharmaceutical Executive marks the occasion by gathering perspectives from pharma and life sciences leaders on this year's WHO theme: "Together for health. Stand with science." Contributors draw on conversations about vaccine confidence, drug pricing policy, and drug discovery to argue that science is not simply a body of knowledge but a process, one that depends on rigorous evidence, transparent communication, and sustained institutional investment to translate into outcomes that reach patients.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
